Promega Corporation
$17.3K 24 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Helios Cardio Inc
Helios Cardio Inc reported $17,351.35 across General Payments, Research, and Ownership to 29 physicians and teaching hospitals across 29 transactions.
- $17.4K Below-median payer
- All-tracks total
- 29 Below-median volume
- Transactions
- 29 Below-median reach
- Recipients
- −$8.2K
- General Payments vs PY2023
Helios Cardio Inc reported $17,351.35 across all CMS Open Payments tracks (General + Research + Ownership) to 29 physicians and teaching hospitals in Program Year 2024 - ranking #1557 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $17,351.35, averaging $598.32 per recipient.
How Helios Cardio Inc's $17.4K all-tracks total breaks down
Helios Cardio Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer helios-cardio-inc Helios Cardio Inc
$17.4K · #1557/1,925 · 0.0% industry · PY2024
- TOT $17.4K
- RANK #1557
- SHARE 0.0%
- TXN 29
- RCP 29
- CAT 2
- GEN $17.4K
- ΔGEN −$8.2K
- TOP1 80.7%
- PY 2024
Volume peers
Nearest volume peer: Promega Corporation ($17.3K)
Helios Cardio Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Helios Cardio Inc's CMS-reported General Payments decreased by $8.2K (−32.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: HELIOS CARDIO INCPY2024: HELIOS CARDIO INC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $25,551.06
- PY2024
- $17,351.35
What the Data Shows for Helios Cardio Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Helios Cardio Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $14.0K, accounting for 80.7% of this company's General Payments and 7 transactions.
General Payment Breakdown by Type
Across 2 types of general payments, Helios Cardio Inc's largest category was "Consulting Fee" at $14.0K - 80.7% of General Payments.
How Helios Cardio Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $14.0K | 7 | 80.7% |
| Food and Beverage | $3.4K | 22 | 19.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $15,107.97 (87.1%) of $17,351.35 in this company's General Payments records across 20 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Helios Cardio Inc
The five named recipients with the highest reported General Payments from this company
- 1
Niv Ad
$14,000.00 across 7 reported transactions
- 2
Clayton Kaiser
$349.93 across 3 reported transactions
- 3
Babatunde Yerokun
$262.32 across 2 reported transactions
- 4
Manish Kanubhai Patel
$247.86 across 1 reported transactions
- 5
John Zaki
$247.86 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Helios Cardio Inc ranks #1557 of 1,925 by total payments (bottom 19% by spend) but is notably more concentrated than that alone would suggest -- #243 of 1,838 by HHI (top 13% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Milestone Scientific Inc. : $1.3M total payments, HHI 6693
- Volpara Health, Inc : $152.0K total payments, HHI 6645
- Epien Medical, Inc. : $7.0K total payments, HHI 6624
- Esteve Pharmaceuticals LLC : $93.5K total payments, HHI 6597
- Philadelphia Medical Management Company LLC : $174.9K total payments, HHI 6579
- Bernhard Foerster GmbH : $347.7K total payments, HHI 6541
- Helios Cardio Inc (this company) : $17.4K total payments, HHI 6534
- Instrumentation Laboratory Company : $1.4M total payments, HHI 6528
- KARL STORZ SE & Co. KG : $39.6K total payments, HHI 6505
- Novocure GmbH : $19.1K total payments, HHI 6485
- Prolaio, Inc. : $8.5K total payments, HHI 6466
- Catalent Pharma Solutions, LLC : $6.3K total payments, HHI 6454
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Helios Cardio Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Helios Cardio Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Helios Cardio Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Afaxys, Inc.
$17.3K 28 recipients
Compare payment profiles
Rattan And Associates
$17.3K 92 recipients
Compare payment profiles
Body Vision Medical Inc.
$17.5K 98 recipients
Compare payment profiles
Avyxa Pharma, LLC
$17.2K 40 recipients
Compare payment profiles
Agiliti Surgical, Inc.
$17.5K 311 recipients
Compare payment profiles
Put this to use
Helios Cardio Inc ranks #1557 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Helios Cardio Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.